Literature DB >> 2105543

Coagulation factors and the increased risk of stroke in nonvalvular atrial fibrillation.

C Gustafsson1, M Blombäck, M Britton, A Hamsten, J Svensson.   

Abstract

We studied whether hemostatic abnormalities contribute to the increased risk of stroke in patients with nonvalvular atrial fibrillation. Hemostatic function was studied in four age-matched groups: 20 patients with nonvalvular atrial fibrillation and a previous ischemic stroke, 20 patients with nonvalvular atrial fibrillation without a previous stroke, 20 stroke patients with sinus rhythm, and 40 healthy controls. Both groups with nonvalvular atrial fibrillation had significantly higher concentrations of von Willebrand factor, factor VIII:C, fibrinogen, D-dimer (a fibrinolytic product), beta-thromboglobulin, and platelet factor 4; a significantly higher fibrinogen/antithrombin ratio; and significantly higher spontaneous amidolytic activity than the healthy controls. Prekallikrein levels were significantly lower in both groups with nonvalvular atrial fibrillation. Stroke patients with sinus rhythm had normal hemostatic function, normal concentrations of platelet-related factors, and a slightly increased concentration of fibrinopeptide A compared with the healthy controls. Both groups with nonvalvular atrial fibrillation differed from the stroke patients with sinus rhythm as they did from the healthy controls. No difference in hemostatic function was seen between the nonvalvular atrial fibrillation patients with and without a previous ischemic stroke. Thus, alterations in hemostatic function may contribute to the increased risk of stroke in patients with nonvalvular atrial fibrillation.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2105543     DOI: 10.1161/01.str.21.1.47

Source DB:  PubMed          Journal:  Stroke        ISSN: 0039-2499            Impact factor:   7.914


  45 in total

Review 1.  Chronic and paroxysmal atrial fibrillation: course, prognosis, and stroke risk.

Authors:  T E Cuddy
Journal:  J Thromb Thrombolysis       Date:  1999-01       Impact factor: 2.300

2.  Gender differences in the risk of ischemic stroke and peripheral embolism in atrial fibrillation: the AnTicoagulation and Risk factors In Atrial fibrillation (ATRIA) study.

Authors:  Margaret C Fang; Daniel E Singer; Yuchiao Chang; Elaine M Hylek; Lori E Henault; Nancy G Jensvold; Alan S Go
Journal:  Circulation       Date:  2005-09-12       Impact factor: 29.690

3.  Twenty-Five-Year (1986-2011) Trends in the Incidence and Death Rates of Stroke Complicating Acute Myocardial Infarction.

Authors:  Essa Hariri; Mayra Tisminetzky; Darleen Lessard; Jorge Yarzebski; Joel Gore; Robert Goldberg
Journal:  Am J Med       Date:  2018-05-04       Impact factor: 4.965

Review 4.  Factoring in Factor VIII With Acute Ischemic Stroke.

Authors:  James E Siegler; Alyana Samai; Karen C Albright; Amelia K Boehme; Sheryl Martin-Schild
Journal:  Clin Appl Thromb Hemost       Date:  2015-02-10       Impact factor: 2.389

5.  Atrial fibrillation and stroke: what we know, what's new, and what we should do now.

Authors:  C S Landefeld
Journal:  CMAJ       Date:  1997-09-15       Impact factor: 8.262

6.  Antiplatelet therapy as a modulator of stroke aetiology: a meta-analysis.

Authors:  Christopher A Rajkumar; Christopher N Floyd; Albert Ferro
Journal:  Br J Clin Pharmacol       Date:  2015-07-02       Impact factor: 4.335

7.  Pharmacologic strategies for the prevention of stroke in patients with atrial fibrillation.

Authors:  Greg Flaker; Richard Weachter
Journal:  Curr Treat Options Cardiovasc Med       Date:  2011-10

8.  Nonvalvular atrial fibrillation: evidence for a prothrombotic state.

Authors:  S R Kahn; S Solymoss; K M Flegel
Journal:  CMAJ       Date:  1997-09-15       Impact factor: 8.262

9.  Increased tissue plasminogen activator levels in patients with nonvalvular atrial fibrillation.

Authors:  S R Kahn; S Solymoss; K M Flegel
Journal:  CMAJ       Date:  1997-09-15       Impact factor: 8.262

10.  Atrial fibrillation and hypercoagulability: dependent on clinical factors or/and on genetic alterations?

Authors:  Eleni Hatzinikolaou-Kotsakou; Zarifis Kartasis; Dimitrios Tziakas; Athanasios Hotidis; Dimitrios Stakos; Konstantinos Tsatalas; Georgios Bourikas; Maria E Kotsakou; Dimitrios I Hatseras
Journal:  J Thromb Thrombolysis       Date:  2003-12       Impact factor: 2.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.